Latest / Stock Movers / HSBC Falls, Novartis Rises, UMG Sound Up
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios. Podcasts.
- 0:05Speaker 2: Radio. News.
- 0:08Speaker 1: The Stock Movers Report. Your roundup of companies making moves
- 0:12Speaker 1: in the stock market. Harnessing the power of Bloomberg data.
- 0:16Speaker 1: Let's have a look at some of the stocks on
- 0:17Speaker 1: the move today in Europe. I'm Caroline Hepke with Stephen Carroll.
- 0:20Speaker 1: We're joined by Bloomberg reporter Josh Gorn Warner. Josh, good
- 0:23Speaker 1: to speak to you.
- 0:24Speaker 2: Let's start with HSBC, the UK's biggest bank.
- 0:26Speaker 1: Mixed results.
- 0:28Speaker 2: And investors don't seem to like it very much.
- 0:30Speaker 1: Just tell us a bit more about HSBC.
- 0:33Speaker 2: Yeah, good morning. So, the bank delivered a 32% rise
- 0:36Speaker 2: in quarterly profit and a nice $ 1 billion share buyback.
- 0:39Speaker 2: But it doesn't seem to be enough to meet quite
- 0:41Speaker 2: lofty expectations of investors. They were anticipating even stronger growth
- 0:46Speaker 2: and some were even looking for a better outlook to
- 0:48Speaker 2: be issued today. The rise in profits was driven by
- 0:52Speaker 2: higher interest rates, robust inflows for its wealth division, and
- 0:55Speaker 2: also some lower credit losses than expected. But Goldman Sachs
- 0:59Speaker 2: said the miss on net interest income suggests the benefit
- 1:03Speaker 2: of the improved rate backdrop may be less than previously hoped.
- 1:06Speaker 2: And the bank also flagged some pressure on deposits in
- 1:09Speaker 2: the U.K. and Hong Kong. And that prompted Jefferies to
- 1:12Speaker 2: suggest that its guidance out to 2028 may actually be
- 1:15Speaker 2: somewhat ambitious. HSB shares were weak in Hong Kong, currently
- 1:20Speaker 2: down about 5.5. The weakness is bleeding through to the
- 1:23Speaker 2: European Open. Shares in London are down about 7% at
- 1:26Speaker 2: present and at their lowest level since May. Things a
- 1:30Speaker 2: bit more positive in terms of investor reception, though, to
- 1:32Speaker 2: the numbers out of the Swiss drugmaker Novartis.
- 1:35Speaker 1: Yes.
- 1:36Speaker 2: So, Novartis up about 2% this morning after topping expectations
- 1:40Speaker 2: and raising its guidance for the rest of the year.
- 1:43Speaker 2: Growth from newer medicines is offsetting the hit from generic competition.
- 1:47Speaker 2: Novartis now expecting core operating profits to come in flattish
- 1:50Speaker 2: or slightly higher this year. It previously forecast a mild decline,
- 1:55Speaker 2: so not too much of a blowout guidance raise, but
- 1:57Speaker 2: it is reassuring investors. These results come as Novartis is
- 2:02Speaker 2: hunting for new medicines as cheaper copies eat into sales
- 2:05Speaker 2: of some of its former bestsellers. Vontabel said that the
- 2:08Speaker 2: profit beat was surprisingly good considering the amount of generic
- 2:11Speaker 2: competition starting to impact several drugs. And, you know, this
- 2:15Speaker 2: situation has been under the spotlight. Three recent clinical trial
- 2:18Speaker 2: setbacks have been in focus. And that is also raising
- 2:21Speaker 2: the stakes for the remaining treatments in the pipeline. So,
- 2:24Speaker 2: you know, questions remain on the future. But Novartis is
- 2:26Speaker 2: providing some reassurance today. Okay.
- 2:29Speaker 1: Lastly, Universal Music Group reaction to what may happen next
- 2:34Speaker 1: for this business. Yeah.
- 2:36Speaker 2: So, I mean, outside the world of earnings, we've got
- 2:38Speaker 2: the world's largest record company. You know, this is home
- 2:40Speaker 2: to acts like Taylor Swift and Kendrick Lamar. It's gaining
- 2:44Speaker 2: on reports that it previously discussed going private with a
- 2:46Speaker 2: few prominent Wall Street firms. It held preliminary talks with
- 2:50Speaker 2: private equity groups, including Apollo, TPG and Blackstone. The conversations
- 2:55Speaker 2: did not progress and Universal has not put itself up
- 2:57Speaker 2: for sale, according to people familiar with the matter. But still,
- 3:01Speaker 2: this news is providing a boost because the share price
- 3:04Speaker 2: has sagged and has prompted many at the company and
- 3:08Speaker 2: on Wall Street to wonder whether the music giant would
- 3:10Speaker 2: be better off as a private firm. The stock is
- 3:12Speaker 2: down 27% this year. It's below its IPO price when
- 3:17Speaker 2: it went public in 2021. And notably, Universal was already
- 3:21Speaker 2: a takeover target earlier this year. One of its shareholders
- 3:24Speaker 2: wanted to make an offer and move it to the U.S.
- 3:26Speaker 2: in the hope of a higher valuation. But this was
- 3:29Speaker 2: rejected despite its biggest investor agreeing that the firm is undervalued. So,
- 3:34Speaker 2: one to keep an eye on for sure.
- 3:36Speaker 1: The Stock Movers Report from Bloomberg Radio. Check back with
- 3:40Speaker 1: us throughout the day for the latest roundup of companies
- 3:43Speaker 1: making news on Wall Street. And for the latest market-moving headlines,
- 3:47Speaker 1: listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg.com,
- 3:52Speaker 1: and on Apple CarPlay and Android Auto with the Bloomberg
- 3:55Speaker 1: Business app.